【摘要】 目的观察阿帕替尼治疗晚期恶性肿瘤患者的临床疗效及安全性。方法选取医院肿瘤中心收治的晚期恶性肿瘤患者75例进行临床试验研究,随机分为观察组38例和对照组37例。对照组仅行安慰剂和最佳支持治疗,观察组在支持治疗基础上加用阿帕替尼治疗,比较2组治疗效果、病情稳定控制率、生存时间、不良反应情况。结果观察组客观缓解率44. 74%、病情控制率为92. 11%,均高于对照组的21. 62%、64. 86%(P <0. 05或P <0. 01); 2组无进展生存期(PFS)时间比较差异无统计学意义(P> 0. 05);观察组总生存期(OS)为(23. 6±3. 3)个月,长于对照组的(7. 4±1. 5)个月(P <0. 01);观察组高血压发生率为44. 74%,高于对照组的16. 22%(P <0. 01); 2组其他不良反应发生率比较差异无统计学意义(P> 0. 05)。结论阿帕替尼治疗晚期恶性肿瘤患者的效果显著,值得临床推广应用。更多还原

【Abstract】 Objective To observe the clinical efficacy and safety of apatinib in the treatment of advanced malignant tumors. Methods Seventy-five patients with advanced malignant tumors were randomly divided into observation group( 38cases) and control group( 37 cases). The control group was treated with placebo and supportive therapy,while the observation group was treated with Apatinib on the basis of supportive therapy. The therapeutic effect,stable disease control rate,survival time and adverse reactions were compared between the two groups. Results The objective remission rate and disease control rate of the observation group were 44. 74% and 92. 11%,respectively,higher than those of the control group( 21. 62% and 64. 82%,P < 0. 05 or P < 0. 01). There was no significant difference in PFS time between the two groups( P > 0. 05). The OS time in the observation group was( 23. 6 ± 3. 3) months,longer than that in the control group( 7. 4 ±1. 5) months( P < 0. 01). The incidence of hypertension in the observation group was 44. 74%,higher than that in the control group( 16. 22%,P < 0. 01). There was no significant difference in the incidence of other adverse reactions between the two groups( P > 0. 05). Conclusion Apatinib is effective in the treatment of advanced malignant tumors,which is worthy of clinical application.更多还原